Antibodies, Monoclonal - Pharmacology
Research News and Information

Sunday, November 22, 2009

A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.

21 Oct 2009 A workshop sponsored by the National Cancer Institute and the US Food and Drug Administration addressed past lessons learned and ongoing challenges faced in biomarker development and drug and biomarker codevelopment. Participants agreed that ... Read more...

Antigen-dependent rescue of nose-associated lymphoid tissue (NALT) development independent of LTbetaR and CXCR5 signaling.

29 Sep 2009 Nose-associated lymphoid tissue (NALT) in the rodent upper respiratory tract develops postnatally and is considered to be independent of several factors known to be involved in the organogenesis of LN and Peyer's patches (PP). In this study we ... Read more...

Concurrent infection with Heligmosomoides polygyrus suppresses anti-Plasmodium yoelii protection partially by induction of CD4(+)CD25(+)Foxp3(+) Treg in mice.

29 Sep 2009 Malaria and intestinal nematode infection are widespread and co-infection frequently occurs. We investigated whether co-infected intestinal nematodes modulate immunity against co-existing malaria parasites. Infection of C57BL/6 mice with Plasmodium ... Read more...

Latest indexed articles for 'Antibodies, Monoclonal - Pharmacology'

These are the very latest articles for this heading:

• A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. 21 Oct 2009
• Antigen-dependent rescue of nose-associated lymphoid tissue (NALT) development independent of LTbetaR and CXCR5 signaling. 29 Sep 2009
• Concurrent infection with Heligmosomoides polygyrus suppresses anti-Plasmodium yoelii protection partially by induction of CD4(+)CD25(+)Foxp3(+) Treg in mice. 29 Sep 2009
• Plasmacytoid DC promote priming of autoimmune Th17 cells and EAE. 29 Sep 2009
• Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacity. 29 Sep 2009
• Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. 29 Sep 2009
• In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood. 29 Sep 2009
• The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%? 20 Sep 2009
• [TNF-alpha blocking therapy in chronic inflammatory bowel disease] 18 Sep 2009
• Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. 10 Sep 2009
• Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. 6 Sep 2009
• Emerging therapies for B-cell non-Hodgkin lymphoma. 30 Aug 2009
• Anti-vascular endothelial growth factor activity in the bevacizumab and triamcinolone acetonide combination for intravitreal use. 30 Aug 2009
• Effects of low-molecular-weight heparin on adhesion and vesiculation of phospholipid membranes: a possible mechanism for the treatment of hypercoagulability in antiphospholipid syndrome. 30 Aug 2009
• CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma. 30 Aug 2009
• Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1. 30 Aug 2009
• Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes. 30 Aug 2009
• Drugs for inflammatory bowel disease. 30 Aug 2009
• Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. 30 Aug 2009
• TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Antibodies, Monoclonal'

Definition: Antibodies produced by clones of cells such as those isolated after hybridization of activated B LYMPHOCYTES with neoplastic cells. These hybrids are often referred to as HYBRIDOMAS.

Registry Number: 0

Descriptor UI: D000911

Alternative terms: Antibodies, Monoclonal; Monoclonal Antibodies;

Related Mesh Headings: Hybridomas;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; biosynthesis; blood; cerebrospinal fluid; classification; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacology; physiology; poisoning; radiation effects; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; pharmacokinetics;

Pharmacological Action: Immunologic Factors;

Tree Number: D12.776.124.486.485.114.224; D12.776.124.790.651.114.224; D12.776.377.715.548.114.224;

History Note: 82

Technical Notes: do not coordinate with ANTIBODY FORMATION for biosyn; ANTIBODY-TOXIN CONJUGATES is available as a toxin carrier: see note there